Urology
 |
|
13 november 2019 01:04:57 |
| Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214 (European Urology) |
|
Tweet In CheckMate 214, a consistent efficacy benefit with nivolumab plus ipilimumab over sunitinib was observed among patients with one, two, three, or four to six International Metastatic Renal Cell Carcinoma Database Consortium risk factors, suggesting that all patients with intermediate- or poor-risk advanced renal cell carcinoma benefit from nivolumab plus ipilimumab, independent of the number of risk factors. |
| 309 viewsCategory: Urology |
 A randomized trial comparing bipolar transurethral vaporization of the prostate with GreenLight laser (xps-180watt) photoselective vaporization of the prostate for treatment of small to moderate benign prostatic obstruction: outcomes after 2 years (BJU International)The Complexity of Complications: How Do We Estimate Morbidity and Target Improvements Following Radical Cystectomy? (European Urology) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page